Enlivex Ltd. (ENLV) Fair Value 2026

ENLV · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.4 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-07-13, Enlivex Ltd. (ENLV) trades at $6.67, approximately 3943% above CirclFi’s Bayesian DCF fair value of $0.16. QOC: 2.4/10. Value Trap Risk: 6/100 (SAFE). 12/13 models active.

Key Facts

Ticker
ENLV
Price
$6.67
Quality Score
2.4/10
Value Trap Risk
6/100
Models Active
12/13
Last Updated
Strength: Earnings Power Value suggests +74.8% upside with 39% confidence
Risk: Below-average Quality Score of 2.4/10 signals weak fundamentals

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($6.67)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.16 -97.5%
Earnings Power Value
Medium Conviction
$11.66 +74.8%
CUCE Ensemble
Low Conviction
$1.48 -77.8%
First Chicago
Low Conviction
$1.07 -84.0%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Enlivex Ltd. (ENLV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Enlivex Ltd. at its current price of $6.67. The composite intrinsic value is estimated at $9.45 (+41.7% average return), with 7 models flagging overvaluation risk. The most optimistic model, FTNN, places fair value at $34.43 (+416.2%), while Bayesian DCF — the most conservative — estimates $0.16 (-97.5%). This +513.7% gap reflects genuine analytical uncertainty about Enlivex Ltd.'s intrinsic worth.

What Do the Models Say About ENLV?

12 of 13 models are currently active for ENLV. Of these, 5 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates ENLV's intrinsic value at $0.16, implying -97.5% downside from the current price. See which stocks rank higher →

How Does ENLV Rank in Pharmaceutical Preparations?

Among 440 Pharmaceutical Preparations stocks, ENLV ranks #405 by Quality of Company score. CirclFi's QOC score of 2.4/10 evaluates 32 fundamental signals. A score of 2.4 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Enlivex Ltd. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ENLV should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ENLV a Value Trap?

CirclFi's Value Trap algorithm assigns ENLV a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Enlivex Ltd.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Enlivex Ltd.'s fundamental quality profile registers 2.4/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +513.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENLV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ENLV's 12 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Enlivex Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Enlivex Ltd.

What is Enlivex Ltd.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Enlivex Ltd. (ENLV) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.16. The Quality of Company score is 2.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENLV overvalued or undervalued right now?

At $6.67, 5 of 12 active models suggest ENLV may be undervalued, while 7 indicate potential overvaluation. The assessment depends on which methodology best fits Enlivex Ltd.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 2.4 mean for ENLV?

Enlivex Ltd.'s QOC of 2.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ENLV?

CirclFi analyzes ENLV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is ENLV a value trap in 2026?

Enlivex Ltd.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on ENLV.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access